-
Product Insights
Mitochondrial Myopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Mitochondrial Myopathy - Drugs In Development, 2023’, provides an overview of the Mitochondrial Myopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mitochondrial Myopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Drugs In Development, 2023’, provides an overview of the Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Friedreich Ataxia – Drugs In Development, 2023
Global Markets Direct’s, ‘Friedreich Ataxia - Drugs In Development, 2023’, provides an overview of the Friedreich Ataxia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Friedreich Ataxia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Retinal Degeneration – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinal Degeneration - Drugs In Development, 2023’, provides an overview of the Retinal Degeneration pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinal Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Duchenne Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Duchenne Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Duchenne Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Recessive X Chromosome Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Recessive X Chromosome Disorders - Drugs In Development, 2023’, provides an overview of the Recessive X Chromosome Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recessive X Chromosome Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IXC-103 in Friedreich Ataxia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IXC-103 in Friedreich Ataxia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IXC-103 in Friedreich AtaxiaDrug Details:IXC-103 (dimethyl fumarate) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ETH-155008 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ETH-155008 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ETH-155008 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:ETH-155008 is...